ArticleBiodegradation2025
Bioremediation of methotrexate by Pleurotus ostreatus pellets: effects on morphology and biotransformation insights.
Article in Biodegradation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Assessment of Rhizopus stolonifer tolerance to methotrexate: morphological responses and biodegradation limitations.Archives of microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Methotrexate (MTX), a widely used antineoplastic drug, poses significant environmental risks due to its persistence and toxicity. This study evaluated the potential of Pleurotus ostreatus fungal pellets for MTX degradation and investigated the underlying removal mechanisms and morphological effects. Fungal pellets were produced under optimized conditions and exposed to MTX in minimal media. MTX removal kinetics were assessed using HPLC, and associated enzymatic activity was quantified. Pleurotus ostreatus achieved over 90% MTX removal within five days. The removal process was primarily enzymatic, as demonstrated by the ineffectiveness of heat-inactivated biomass and the lack of impact from cytochrome P450 inhibition. Elevated laccase activity coincided with MTX degradation, suggesting its key role in the biotransformation pathway. Mass spectrometry revealed 16 MTX metabolites, including 7-hydroxymethotrexate and 2-oxoglutaric acid, indicating progressive oxidation, ring cleavage, hydroxylation, and eventual integration into primary metabolism. Scanning electron microscopy showed significant structural degradation of fungal pellets during the process, highlighting stress-induced morphological changes. The findings establish the feasibility of employing P. ostreatus pellets as an environmentally compatible biotechnological tool for the degradation of cytotoxic compounds like MTX. To our knowledge, this is the first report of MTX biotransformation by fungal pellets of P. ostreatus, and it contributes valuable insights into fungal-based bioremediation strategies for pharmaceutical pollutants.
Indexed as
Identifiers
40676268What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.